Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

NCT03780517 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Nonhaematologic Malignancies

Interventions

DRUG: BOS172738

Sponsor

Boston Pharmaceuticals